Diabetes Care 44(7):16221629
The article describes that choice for a patient who tolerates the GLP-1 well but still needs additional glucose-lowering support, and who would rather not add another injectable or push the GLP-1 further
A combination of obesity, reduced activity levels, and aging may have contributed to this disorder ( L-carnitine is involved in transports long-chain fatty acids from the cytoplasm to the mitochondria, as well as the beta-oxidation of fatty acid indirectly
Providers who submit PAs regularly learn to include the magic phrases: "failed 6-month medically supervised weight loss program," "documented BMI 32 with hypertension and prediabetes," "requesting Wegovy for treatment of obesity-related comorbidities." The coverage difference between Wegovy, Ozempic, and compounded semaglutide All three contain semaglutide, but Ambetter treats them as separate drugs with separate coverage rules: The loophole many patients attempt: ask the provider to prescribe Ozempic off-label for weight loss
(Hint: These solutions can be supported either through an organizations current pharmacy benefit manager or through a full carve-out for GLP-1 weight loss medications.) Join us in pioneering a future where better health is accessible to all